WO2010141143A3 - Engineered avirulent bacteria strains and use in medical treatments - Google Patents

Engineered avirulent bacteria strains and use in medical treatments Download PDF

Info

Publication number
WO2010141143A3
WO2010141143A3 PCT/US2010/027245 US2010027245W WO2010141143A3 WO 2010141143 A3 WO2010141143 A3 WO 2010141143A3 US 2010027245 W US2010027245 W US 2010027245W WO 2010141143 A3 WO2010141143 A3 WO 2010141143A3
Authority
WO
WIPO (PCT)
Prior art keywords
engineered
avirulent
medical treatments
bacteria strains
strains
Prior art date
Application number
PCT/US2010/027245
Other languages
French (fr)
Other versions
WO2010141143A2 (en
Inventor
Nabil Arrach
Michael Mcclelland
Original Assignee
Vivocure, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivocure, Inc. filed Critical Vivocure, Inc.
Publication of WO2010141143A2 publication Critical patent/WO2010141143A2/en
Publication of WO2010141143A3 publication Critical patent/WO2010141143A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Abstract

Provided in part herein are avirulent bacterial compositions suitable for use as medicaments for the treatment of various tumors. Also provided in part are methods for identifying and/or generating avirulent bacterial strains or engineered avirulent bacterial strains that can be formulated as medicaments. Also provided in part are methods of cancer treatment utilizing engineered avirulent bacteria as described herein. Engineered strains as described herein show normal or increased fitness in tumor tissue, while exhibiting reduced fitness in normal tissue. Compositions described herein may prove useful for the treatment of other medical conditions.
PCT/US2010/027245 2009-04-21 2010-03-12 Engineered avirulent bacteria strains and use in medical treatments WO2010141143A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17133009P 2009-04-21 2009-04-21
US61/171,330 2009-04-21

Publications (2)

Publication Number Publication Date
WO2010141143A2 WO2010141143A2 (en) 2010-12-09
WO2010141143A3 true WO2010141143A3 (en) 2011-03-03

Family

ID=43298380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/027245 WO2010141143A2 (en) 2009-04-21 2010-03-12 Engineered avirulent bacteria strains and use in medical treatments

Country Status (1)

Country Link
WO (1) WO2010141143A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
CN105462907A (en) * 2015-11-02 2016-04-06 四川农业大学 Attenuation salmonella typhimurium and construction method and application
WO2017079699A1 (en) * 2015-11-04 2017-05-11 The Broad Institute, Inc. Multiplex high-resolution detection of micro-organism strains, related kits, diagnostics methods and screening assays

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018837A1 (en) * 1995-11-22 1997-05-29 University Of Maryland At Baltimore Novel non-pyrogenic bacterial strains and use of the same
WO1999013053A1 (en) * 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
WO1999058146A1 (en) * 1998-05-13 1999-11-18 University Of Maryland, Baltimore ATTENUATED MUTANTS OF SALMONELLA WHICH CONSTITUTIVELY EXPRESS THE Vi ANTIGEN
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018837A1 (en) * 1995-11-22 1997-05-29 University Of Maryland At Baltimore Novel non-pyrogenic bacterial strains and use of the same
WO1999013053A1 (en) * 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
WO1999058146A1 (en) * 1998-05-13 1999-11-18 University Of Maryland, Baltimore ATTENUATED MUTANTS OF SALMONELLA WHICH CONSTITUTIVELY EXPRESS THE Vi ANTIGEN
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUTRET, N. ET AL.: "Identification of new genes involved in the virulence of Listeria monocytogenes by signature-tagged transposon mutagenesis.", INFECT. IMMUN., vol. 69, no. 4, April 2001 (2001-04-01), pages 2054 - 2065, XP002326447, DOI: doi:10.1128/IAI.69.4.2054-2065.2001 *
METTS, J. ET AL.: "Characterization of three Agrobacterium tumefaciens avirulent mutants with chromosomal mutations that affect induction of vir genes.", J. BACTERIOL., vol. 173, no. 3, February 1991 (1991-02-01), pages 1080 - 1087 *

Also Published As

Publication number Publication date
WO2010141143A2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
UA107667C2 (en) Medical compounds stimulating activity of pyruvate kinase m2, compositions on their basis and use in the treatment of cancer
WO2018033254A3 (en) Rna for cancer therapy
WO2009100716A3 (en) Implantable products comprising nanoparticles
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2009105513A3 (en) Novel compounds and methods for therapy
EP4140487A8 (en) Combination therapy for treating cancer
MX340533B (en) 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections.
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2011007930A (en) Crystalline insulin-conjugates.
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
MX343135B (en) Fumagillol type compounds and methods of making and using same.
EP2440210A4 (en) Methods for treating gastrointestinal disorders
MX2010000465A (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
SG164368A1 (en) Treatment of cancer
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2009095261A3 (en) Vaccine compositions
WO2011050302A3 (en) Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
EP1971338B8 (en) Combination of zd6474 and pemetrexed
EP2596744A3 (en) Guide member
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2008060945A3 (en) Diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10783743

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10783743

Country of ref document: EP

Kind code of ref document: A2